Resources

Treating Viral Infections with mRNA-Encoded Cas13

The potential of gene editing as a therapeutic has come to fruition in the past several years, as clinical data from various studies has shown very positive results. Merging that potential with novel mRNA technologies—which have also demonstrated their value and versatility during the COVID-19 pandemic—could provide scientists and clinicians with an unmatched weapon in the arsenal to fight various diseases. In particular, Cas13 has been used to target RNA viruses in cell culture, but only recently has efficacy in animal models been demonstrated.

in this webinar, cohosted by GEN and The CRISPR Journal, that is diving deep into the burgeoning world of mRNA research and therapeutics. Our distinguished guest for this event, Dr. Philip Santangelo, will introduce important aspects of how to use mRNA to express Cas13 and use it as an antiviral agent. Additionally, Dr. Santangelo will discuss guide design, screening, the importance of controls, and how to apply this approach in vivo against multiple pathogens

Challenges and Considerations for mRNA Therapeutic Development

Due to its extreme potential to revolutionize the biopharma industry, the benefits of mRNA as a novel therapeutic are well known. However, the path leading to the development of mRNA medicines can be challenging and is often less discussed. Qualities like nucleic acid stability, immunogenicity, and delivery of the final product are all critical factors that face mRNA medicines and need to be addressed more frequently. Thankfully, novel methodologies and techniques to assist drug developers are on the rise and have the potential to streamline production workflows and increase production and efficiency.

This is the second webinar in a series of four, cohosted by GEN and The CRISPR Journal, that is diving deep into the burgeoning world of mRNA research and therapeutics. Our distinguished guest for this event, Dr. Edward Miracco, will take us through his extensive experience with mRNA chemistry, sequence design, and commercial-scale production. Dr. Miracco has faced many challenges in his work and will tell us about several vital considerations that could significantly aid your mRNA research endeavors.

Influenza mRNA Vaccines: Mechanisms and Methodologies

The power of mRNA vaccines became well established due to the COVID-19 pandemic, but we are just beginning to scratch the surface of their therapeutic versatility. Numerous global projects are underway to employ mRNA technology to combat human diseases such as cancer, HIV, and influenza. In a four-part webinar series over the next several months, we will hear from a diverse group of investigators who are at the vanguard of mRNA research and the novel ways they are utilizing this technology.

In this first webinar, our distinguished speaker, Dr. Norbert Pardi, will be discussing cutting-edge work on the development of broadly protective mRNA-based influenza vaccines. Not only will he discuss the mechanism of action of mRNA vaccines, Dr. Pardi will also tell us how his laboratory utilized a lipid nanoparticle-encapsulated, nucleoside-modified mRNA vaccine platform to deliver a combination of conserved influenza virus antigens.

TIDES mRNA Technologies Digital Week: Analytical Methods for a Well Characterized mRNA Drug Substance

Though much of the regulatory filing requirements for mRNA-based therapeutics can be compared with those for traditional biologics, others are not yet well defined. Like traditional biologic products and processes, mRNA-based products require controls on the quality of the starting material (including cell banking), consistency of manufacturing processes, identification of critical process parameters, clearance of impurities, establishment of environmental controls to meet safety requirements, and the thorough characterization of structure, purity, and efficacy. This has posed some challenges in analytical method development to ensure qualification for intended use. We discuss some of these challenges and solutions to support the requirements for characterization of structure, purity, and efficacy of an mRNA Drug Substance.

mRNA Modifications that Matter: Modified Uridine as a Therapeutic Tool

In vitro transcribed (IVT) mRNA has become an effective and scalable therapeutic modality for a wide range of disease indications. It has been shown that modifications to wild-type uridine may improve the efficacy of these therapeutics. To aid in the synthesis of these compounds, TriLink is developing an extensive platform to manufacture modified uridine and mRNA at both GMP quality and scale.

Fine-Tuning mRNA Fate and Function: Modified Uridine as a Therapeutic Tool

In this presentation Cory Smith, Application Scientist, TriLink BioTechnologies will discuss in vitro transcribed (IVT) mRNA and how it has become an effective and scalable therapeutic modality for a wide range of disease indications. 

Therapeutic Advances Using In Vivo CRISPR Genome Editing

In this webinar, Dr. Laura Sepp-Lorenzino Chief Scientific Officer at Intellia, will share the company's progress in both in vivo and ex vivo genome editing approaches. In particular, she will discuss the recent advances made regarding NTLA-2001—the first-ever investigational CRISPR-Cas9 therapy candidate to be systemically delivered for the treatment of ATTR amyloidosis.

The Future of RNA Therapeutics is Modular

In this webinar from GEN and The CRISPR Journal, Professor Dan Peer will discuss the state of RNA-based therapeutics, particularly developing a self-assembled modular platform that enables the construction of a theoretically unlimited repertoire of RNA-targeted carriers. He will present a novel approach for delivering modified mRNA to specific cell types in vivo utilizing this platform.

mRNA Applications: Development of mRNA and its Applications

In recent years, the development of mRNA and its applications has dramatically expanded across therapeutic areas. The clinical development of mRNA products includes a number of unique features and considerations that are rooted in mRNA’s molecular characteristics. In this webinar, May Guo, MBA, Director of Business Development at TriLink BioTechnologies, will highlight important aspects to consider as you develop your mRNA tools and drugs.

mRNA Basics: Analytical Testing for mRNA Therapeutics

Analytical testing is a key component of every mRNA therapeutic program. In this mRNA Basics webinar, Jessica Madigan, Director Business Development, GMP at TriLink, will discuss analytical testing considerations for mRNA and common mistakes to avoid.

TIDES mRNA Therapeutics & Vaccines Digital Week-Streamlined mRNA Synthesis with CleanCap^® Technology

In this presentation, Jordana Henderson MS, Scientist at TriLink BioTechnologies will explore the manufacturing benefits of IVT synthesis using CleanCap Cap1 analogs for highly functional mRNA as shown in mice.

mRNA Basics: Getting Started with GMP mRNA Manufacturing

More scientists than ever are embracing mRNA technology for vaccine and therapeutic applications. However, the road to GMP manufacturing can be challenging for those new to the field. In this mRNA Basics webinar, Sawan Shah, Sr. Manager, Business Development at TriLink, will cover the key considerations for transitioning your mRNA program to GMP. 

mRNA Basics: Optimizing Your mRNA Coding Sequence

mRNA sequence optimization is an important step in the design of mRNA vaccines and therapeutics. In this mRNA Basics webinar, Cory Smith, Senior Technical Inside Sales Specialist at TriLink, will walk through the strategies and resources for coding sequence optimization. 

World Vaccine Congress 2021: Rapid mRNA manufacturing for Vaccine Development

In this webinar, Jessica Madigan, Director of Business Development, GMP at TriLink, describes the advantages and design considerations of using mRNA in your vaccine program.

Precision Genome Editing without Double-Strand Breaks - Featuring Dr. David Liu

In this webinar, Dr. David Liu describes the development of two approaches to precision genome editing—base editing and prime editing—that do not require double-strand DNA breaks (DSBs).

mRNA Basics: Capping Strategies for mRNA Manufacturing

Multiple mRNA capping technologies are available today, each with advantages and disadvantages. In this mRNA Basics webinar, Scott Taylor, MS, Senior Alliance Manager at TriLink, will discuss common mRNA capping strategies and which applications they are best suited for. A live Q&A session will follow the presentation.

mRNA Basics: Strategies to Minimize Innate Immune Response

The innate immune response is critical to consider when designing your mRNA sequence and manufacturing process. In this mRNA Basics webinar, Cory Smith, Senior Technical Inside Sales Specialist at TriLink, will highlight several strategies for minimizing the innate immune response to mRNA therapeutics. A live Q&A session will follow the presentation.

mRNA Day 2020: Celebrating the Past, Present, and Future of mRNA

In celebration of mRNA Day 2020, TriLink proudly presents back-to-back webinars by two pioneers of the mRNA therapeutic platform: Dr. Katalin Karikó (BioNTech) and Dr. Drew Weissman (University of Pennsylvania). Dr. Karikó provides an overview of the history of mRNA therapeutics, while Dr. Weissman offers his perspective on the future of mRNA medicines. A moderated Q&A session follows the presentations.

SpotLight Workshop: Emerging mRNA Applications

As new technologies are developed around the use of mRNA, exciting applications emerge. TriLink is a proven leader in supporting cutting-edge mRNA research, from unique raw materials to custom synthesis. Join TriLink technical experts, Taylor McReynolds, MS and Cory Smith for this workshop on several noteworthy applications supported by TriLink mRNA services, including base editing, riboswitches, pandemic response and more.

SpotLight Workshop: Applications for Modified NTPs

From sequencing to therapeutics, NTPs are utilized in a wide range of applications. Hundreds of different modified NTPs are available as catalog products, and it can be overwhelming to find the right NTP for your project. In this workshop, TriLink technical experts Nick Ko and Taylor McReynolds, MS, will discuss the various different NTP modifications that exist and how to best utilize them to benefit your research, with a special emphasis on optimizing mRNA for therapeutic applications.

Novel Methods for Synthesizing Self-Amplifying RNA Vaccines Improve Yields and Accelerate GMP Manufacturing

In this video Dr. Anton McCaffrey, Senior Director of Emerging Science and Innovation, at TriLink BioTechnologies discusses synthesizing self-amplifying RNA vaccines to improve yields and accelerate GMP manufacturing.

GMP Manufacturing of Messenger RNA Therapeutics and Vaccines: Case Study of a Self-Amplifying SARS CoV-2 Vaccine

In this presentation Jessica Madigan, Director of Business Development will discuss, investigative mRNA vaccine programs scale from target-centric research to progressing candidates through the drug development process, challenges arise when determining the optimal path forward. 

SpotLight Workshop: CleanCap AU

This webinar presented by Dr. Anton McCaffrey will focus on the uses and value of CleanCap AU. CleanCap Reagent AU is designed for the co-transcriptional capping of mRNA to produce an mRNA with naturally occurring Cap 1.

SpotLight Workshop: CleanCap

We are pleased to introduce a new type of educational event. The TriLink SpotLight Workshops are designed to be focused and impactful sessions with topic experts that allow you to learn and interact with Q&A. Our first workshop is on our proprietary mRNA capping technology — CleanCap^® featuring Dr. Anton McCaffrey, Senior Director of Emerging Science and Innovation, at TriLink BioTechnologies.